# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-26-015557
**Filing Date:** 2026-4
**Character Count:** 8151
**Document Hash:** 0e067f89c3c82355a706ae9a41dd17ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-015557.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001493152-26-015557

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260407

**FILED AS OF DATE**: 20260407

**DATE AS OF CHANGE**: 20260407

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38064
- **FILM NUMBER:** 26845664

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2026

Commission File Number: **001-38064**

**COSCIENS Biopharma Inc.**

(Translation of registrant's name into English)

**c/o Borden Ladner Gervais, LLP**

**22 Adelaide St. West, Suite 3400**

**Bay Adelaide Centre, East Tower**

**Toronto ON M5H 4E3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On April 7, 2026, COSCIENS Biopharma Inc. (the "Company") issued a press release commenting on unusual market activity. A copy of the press release is attached to this Form 6-K as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking statements and includes cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statements.

**Forward-Looking Statements**

The information in this Report on Form 6-K and the exhibit attached hereto and incorporated herein by reference include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and under the provisions of Canadian securities laws. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

Forward-looking statements include, but are not limited to, those relating to the Company's expectations regarding the anticipated benefits and synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company.

Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following:

● the
 results of any insolvency proceedings in respect of the Company's German subsidiaries;

● the
 final legal and accounting implications of any insolvency;

● the
 Company's patented technologies and value-driving products, and development thereof;

● the
 extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related
 products;

● the
 successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan
 from yeast, as well as such products' capability to address unmet needs within the nutraceuticals markets;

● the
 Company's business strategy;

● the
 potential use and effects of tariffs to address the current presidential administration's policy goals, could materially impact
 our costs and revenues, as well as the macroeconomic framework in which we operate;

● the
 Company's positioning in its target markets;

● the
 Company's ability to commercialize its PGX Technology;

● management's
 assumptions, estimates and judgements;

● liquidity
 and capital resources;

● adequacy
 of our financial resources to finance operations and expenditure requirements;

● limitations
 on internal controls over financial reporting; and

● the
 plans, objectives, future outlook and financial position of the Company in general.

Additional risk factors that could cause actual results to differ materially include those risks identified in Item 3. "Key Information – Risk Factors" contained in the Company's most recent Annual Report on Form 20-F filed with the SEC and its other filings and submissions from time to time, including those containing its quarterly and annual results, with the SEC, which are available on the Company's website located at <u>www.cosciensbio.com</u>.

Many of these risks and factors are beyond the Company's control. The Company cautions you not to place undue reliance on these forward-looking statements. All written and oral forward-looking statements attributable to the Company or persons acting on their behalf, are qualified in their entirety by these cautionary statements. Moreover, unless required by law to update these statements, the Company will not necessarily update any of these statements after the date hereof, either to conform them to actual results or to changes in their expectation.

**DOCUMENTS INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [COSCIENS Comments on Unusual Market Activity](ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **COSCIENS Biopharma Inc.** | **COSCIENS Biopharma Inc.** |
| Date: April 7, 2026 | By: | */s/ Giuliano La Fratta* |
|  | Name: | Giuliano La Fratta |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![A green circle in the dark AI-generated content may be incorrect.](ex99-1_001.jpg)

**COSCIENS Comments on Unusual Market Activity**

**TORONTO, ONTARIO, April 7, 2026** – COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("**COSCIENS**" or the "**Company**") is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company's common shares.

**About COSCIENS Biopharma Inc.**

<br> COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company's proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. The Company's common shares are listed on the TSX under the symbol "CSCI" and are listed and posted for trading on the OTCQB® Venture Market under the symbol "CSCIF". For more information, please visit COSCIENS' website at www.cosciensbio.com.

**Issuer Contact:**

Peter H. Puccetti

Interim CEO and Chairman of the Board

pp@cosciensbio.com

Giuliano La Fratta

Chief Financial Officer

glafratta@cosciensbio.com

**Investor Contact:**

IR@cosciensbio.com